

At page 57, line 3, replace "18" with --16--.

At page 58, line 1, replace "19" with --17--.

In the Claims:

Please amend claims ~~24, 25, 28~~ to 32, 34 to 36, and 43 as follows.

B1  
24. (Amended) The polypeptide of claim 23, wherein the polypeptide is human NR8-alpha comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 361st amino acid Ser of SEQ ID NO:1, or a modified human NR8-alpha polypeptide comprising the amino acid sequence of said human NR8-alpha polypeptide with one or more amino acids deleted, added, or substituted with a different amino acid, and being functionally equivalent to said human NR8-alpha polypeptide.

25. (Amended) The polypeptide of claim 23, wherein the polypeptide is human NR8-beta comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 144th amino acid Leu of SEQ ID NO:3, or a modified human NR8-beta polypeptide comprising the amino acid sequence of said human NR8-beta polypeptide with one or more amino acids deleted, added, or substituted with a different amino acid, and being functionally equivalent to said human NR8-beta polypeptide.

B2  
Cm.t  
28. (Amended) The polypeptide of claim 23, wherein the polypeptide is human NR8-gamma comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 538th amino acid Ser of SEQ ID NO:7, or a modified human NR8-gamma polypeptide comprising the amino acid sequence of said human NR8-gamma polypeptide with one or more amino acids deleted, added, or substituted with a different amino acid, and being functionally equivalent to said human NR8-gamma polypeptide.

29. (Amended) The polypeptide of claim 23, wherein the polypeptide is mouse NR8-beta comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 144th amino acid Leu of SEQ ID NO:19, or a modified mouse NR8-beta polypeptide comprising the amino acid sequence of said mouse NR8-beta polypeptide with one or more amino acids

deleted, added, or substituted with a different amino acid, and being functionally equivalent to said mouse NR8-beta polypeptide.

30. (Amended) The polypeptide of claim 23, wherein the polypeptide is mouse NR8-gamma comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 538th amino acid Ser of SEQ ID NO:21, or a modified mouse NR8-gamma polypeptide comprising the amino acid sequence of said mouse NR8-gamma polypeptide with one or more amino acids deleted, added, or substituted with a different amino acid, and being functionally equivalent to said mouse NR8-gamma polypeptide.

B2  
Comtd.  
31. (Amended) The polypeptide of claim 23, wherein the polypeptide is encoded by a nucleic acid that hybridizes to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:2, said polypeptide being functionally equivalent to a human NR8-alpha polypeptide comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 361st amino acid Ser of SEQ ID NO:1.

32. (Amended) The polypeptide of claim 23, wherein the polypeptide is encoded by a nucleic acid that hybridizes to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:4, said polypeptide being functionally equivalent to a human NR8-beta polypeptide comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 144th amino acid Leu of SEQ ID NO:3.

B3  
Comtd.  
34. (Amended) The polypeptide of claim 23, wherein the polypeptide is encoded by a nucleic acid that hybridizes to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:8, said polypeptide being functionally equivalent to a human NR8-gamma polypeptide comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 538th amino acid Ser of SEQ ID NO:7.

35. (Amended) The polypeptide of claim 23, wherein the polypeptide is encoded by a nucleic acid that hybridizes to a nucleic acid comprising the nucleotide sequence of SEQ ID

NO:20, said polypeptide being functionally equivalent to a mouse NR8-beta polypeptide comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 144th amino acid Leu of SEQ ID NO: 19.

B3  
cancel

36. (Amended) The polypeptide of claim 23, wherein the polypeptide is encoded by a nucleic acid that hybridizes to a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 22, said polypeptide being functionally equivalent to a mouse NR8-gamma polypeptide comprising the amino acid sequence from the [1st amino acid Met] 20th amino acid Cys to the 538th amino acid Ser of SEQ ID NO:21.

B3  
cancel

43. (Amended) The nucleic acid of claim 38, wherein the nucleic acid comprises the nucleotide sequence from the [441st nucleotide A] 498th nucleotide T to the 1523rd nucleotide C in SEQ ID NO:2; the nucleotide sequence from the [441st nucleotide A] 498th nucleotide T to the 872nd nucleotide A in SEQ ID NO:4; the nucleotide sequence from the 659th nucleotide A to the 1368th nucleotide C in SEQ ID NO:6; the nucleotide sequence from the [441st nucleotide A] 498th nucleotide T to the 2054th nucleotide C in SEQ ID NO:8; the nucleotide sequence from the [439th nucleotide A] 496th nucleotide T to the 870th nucleotide A in SEQ ID NO:20; or the nucleotide sequence from the [439th nucleotide A] 496th nucleotide T to the 2052nd nucleotide C in SEQ ID NO:22.

Please add new claim ~~51~~ as follows.

B5

51. (New) A hemopoietin receptor NR8 polypeptide produced by the method of claim 46.

In the Drawings:

Please delete Figure 16.

Please delete Figure 17.

Please renumber Figure 18 as Figure 16, as shown in red in the attached copy.

Please renumber Figure 19 as Figure 17, as shown in red in the attached copy.